Figure 7c shows that VEGF-αgal, but not VEGF–DNP, conjugate recruited antibodies to tumors of endometrial, kidney, melanoma, and colon origin, altogether 5 out of 5 tumors tested, reflecting the broad expression pattern of VEGF in tumors and the utility of VEGF aptamer targeting ligand, as we have previously demonstrated in mice24,43. The gene discussed is VEGFA; the disease is melanoma.